Pharmaceuticals, Biotechnology and Life Sciences
ristol-Myers Squibb Company and Infinity Pharmaceuticals have announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo …
Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closely watched clinical trial.
Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog.
The U.S. Food and Drug Administration has approved Bristol-Myers Squibb-marketed Opdivo (nivolumab) to treat patients with advanced form of kidney cancer.
Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. have announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Prime’s colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase 1 development for immunology and oncology indications.
The U.S. Food and Drug Administration (FDA) has today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.